Oral insulin delivery, the challenge to increase insulin bioavailability: Influence of surface charge in nanoparticle system

Int J Pharm. 2018 May 5;542(1-2):47-55. doi: 10.1016/j.ijpharm.2018.02.045. Epub 2018 Mar 6.

Abstract

Oral administration of insulin increases patient comfort and could improve glycemic control thanks to the hepatic first passage. However, challenges remain. The current approach uses poly (d, lactic-co-glycolic) acid (PLGA) nanoparticles (NPs), an effective drug carrier system with a long acting profile. However, this system presents a bioavailability of less than 20% for insulin encapsulation. In this context, physico-chemical parameters like surface charge could play a critical role in NP uptake by the intestinal barrier. Therefore, we developed a simple method to modulate NP surface charge to test its impact on uptake in vitro and finally on NP efficiency in vivo. Various NPs were prepared in the presence (+) or absence (-) of polyvinyl alcohol (PVA), sodium dodecyl sulfate (SDS), and/or coated with chitosan chloride. In vitro internalization was tested using epithelial culture of Caco-2 or using a co-culture (Caco-2/RevHT29MTX) by flow cytometry. NPs were then administered by oral route using a pharmaceutical complex vector (100 or 250 UI/kg) in a diabetic rat model. SDS-NPs (-42 ± 2 mV) were more negatively charged than -PVA-NPs (-22 ± 1 mV) and chitosan-coated NPs were highly positively charged (56 ± 2 mV) compared to +PVA particles (-2 ± 1 mV), which were uncharged. In the Caco-2 model, NP internalization was significantly improved by using negatively charged NPs (SDS NPs) compared to using classical NPs (+PVA NPs) and chitosan-coated NPs. Finally, the efficacy of insulin SDS-NPs was demonstrated in vivo (100 or 250 UI insulin/kg) with a reduction of blood glucose levels in diabetic rats. Formulation of negatively charged NPs represents a promising approach to improve NP uptake and insulin bioavailability for oral delivery.

Keywords: Bioavailability; Charge; Diabetes; Insulin; Nanoparticle; Oral administration.

MeSH terms

  • Animals
  • Biological Availability
  • Blood Glucose / analysis
  • Cell Line
  • Cell Survival / drug effects
  • Coculture Techniques
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Experimental / metabolism
  • Drug Carriers / administration & dosage*
  • Drug Carriers / chemistry
  • Drug Carriers / pharmacokinetics
  • Drug Carriers / therapeutic use
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / pharmacokinetics
  • Hypoglycemic Agents / therapeutic use
  • Insulin / administration & dosage*
  • Insulin / chemistry
  • Insulin / pharmacokinetics
  • Insulin / therapeutic use
  • Lactic Acid / administration & dosage
  • Lactic Acid / chemistry
  • Lactic Acid / pharmacokinetics
  • Lactic Acid / therapeutic use
  • Male
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Nanoparticles / therapeutic use
  • Polyglycolic Acid / administration & dosage
  • Polyglycolic Acid / chemistry
  • Polyglycolic Acid / pharmacokinetics
  • Polyglycolic Acid / therapeutic use
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Rats, Wistar
  • Sodium Dodecyl Sulfate / administration & dosage*
  • Sodium Dodecyl Sulfate / chemistry
  • Sodium Dodecyl Sulfate / pharmacokinetics
  • Sodium Dodecyl Sulfate / therapeutic use
  • Surface Properties

Substances

  • Blood Glucose
  • Drug Carriers
  • Hypoglycemic Agents
  • Insulin
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Sodium Dodecyl Sulfate